#Rare hematology disorders market size | Explore Tumblr posts and blogs

healthcarefuture · 4 days ago

Text

Innovations and Developments Shaping the Future of the Paroxysmal Nocturnal Hemoglobinuria Market

Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare, life-threatening hematologic disorder characterized by the destruction of red blood cells, a process known as hemolysis. This condition is caused by a mutation in the PIGA gene, which leads to the absence of certain proteins on the surface of blood cells. As a result, these cells become vulnerable to attack by the body's own immune system. Paroxysmal Nocturnal Hemoglobinuria often presents with symptoms like dark-colored urine, fatigue, and an increased risk of blood clots, making early diagnosis and treatment crucial.

The market size for paroxysmal nocturnal hemoglobinuria was projected to be 0.36 billion USD in 2022 based on MRFR study.It is anticipated that the market for paroxysmal nocturnal hemoglobinuria would increase from 0.39 billion US dollars in 2023 to 0.7 billion US dollars in 2032. During the projected period (2024-2032), the Paroxysmal Nocturnal Hemoglobinuria Market is anticipated to increase at a CAGR of around 6.73%.

The size of the affected population is small due to the rarity of this disease. PNH primarily affects adults, with an estimated global prevalence of 1-10 cases per million people annually. However, the true size of the affected population might be underreported due to misdiagnosis or delayed diagnosis. Despite its rarity, the impact of Paroxysmal Nocturnal Hemoglobinuria on patients' quality of life and healthcare systems is significant, given its chronic nature and potential for severe complications, including aplastic anemia and acute kidney injury.

Paroxysmal Nocturnal Hemoglobinuria Share

The market share for Paroxysmal Nocturnal Hemoglobinuria therapies is concentrated among a few pharmaceutical companies, given the specialized nature of treatments and the limited patient population. Leading players such as Alexion Pharmaceuticals (now part of AstraZeneca) have dominated this market for years with their pioneering treatment, eculizumab (Soliris), and its successor, ravulizumab (Ultomiris). These therapies are C5 complement inhibitors that reduce hemolysis, providing symptomatic relief and improving patient outcomes.

The high cost of these treatments significantly contributes to the market size, with annual therapy costs often reaching hundreds of thousands of dollars per patient. The North American and European regions currently hold the largest market shares due to better access to advanced healthcare and the availability of high-cost therapies. However, increasing awareness and diagnostic capabilities in Asia-Pacific and Latin America suggest a potential rise in market share in these regions in the coming years.

Paroxysmal Nocturnal Hemoglobinuria Analysis

The analysis of the Paroxysmal Nocturnal Hemoglobinuria market reveals several critical factors influencing its dynamics. First, the rarity of the disease implies a relatively small but high-value market, driven by expensive therapies rather than a large patient volume. The increasing availability of advanced diagnostic tools, such as flow cytometry, has led to earlier and more accurate detection of PNH, contributing to the growth in market demand. Additionally, the introduction of next-generation therapies and biosimilars is expected to alter the competitive landscape by providing more options at potentially lower costs.

Emerging therapies targeting alternative pathways, such as Factor D inhibitors (e.g., iptacopan), offer a promising expansion of the treatment paradigm. These drugs are in various stages of clinical trials and may address unmet needs, especially in patients who do not respond adequately to current therapies. The analysis also points to the importance of ongoing research and development, as well as strategic collaborations among pharmaceutical companies, to drive market growth and innovation.

Paroxysmal Nocturnal Hemoglobinuria Trends

Several trends are shaping the future of the Paroxysmal Nocturnal Hemoglobinuria market.

Increased Focus on Gene Therapy: With advances in genetic research, there is growing interest in developing gene therapies that could potentially offer a cure for PNH by addressing the underlying genetic mutation. Although still in the experimental stage, this trend reflects a shift towards more curative approaches rather than just managing symptoms.

Rising Investment in Biosimilars: As patents for key PNH drugs like Soliris expire, there is a surge in the development of biosimilars. These alternatives promise to make treatment more affordable and accessible, especially in emerging markets.

Expansion of Clinical Trials: There is an increase in the number of clinical trials exploring novel treatment options for PNH. This trend is driven by the need for more effective, less burdensome therapies that can reduce the frequency of administration and side effects.

Personalized Medicine: Advances in genomics are paving the way for personalized treatment plans based on a patient's specific genetic profile. This trend aims to improve outcomes by tailoring therapies to the unique needs of each individual.

Patient Advocacy and Awareness Campaigns: Greater patient advocacy and awareness campaigns are helping to reduce the diagnostic delay associated with Paroxysmal Nocturnal Hemoglobinuria. This is particularly important because early detection can significantly improve treatment outcomes and quality of life for patients.

Reasons to Buy the Reports

Comprehensive Market Analysis: Gain insights into the Paroxysmal Nocturnal Hemoglobinuria market size, share, and future growth potential, including detailed analysis of emerging trends and therapeutic advancements.

Strategic Market Insights: Understand the competitive landscape, key players, and their market strategies to identify potential opportunities and threats in the PNH market.

Investment Opportunities: Evaluate potential investment opportunities in the rapidly evolving PNH therapy market, particularly in emerging regions with increasing diagnostic capabilities.

Clinical Development Insights: Access information on ongoing clinical trials, pipeline drugs, and innovative therapies that may significantly impact the future treatment landscape for PNH.

Patient Demographics and Epidemiology: Get detailed data on patient demographics, prevalence, and diagnosis rates, which are critical for planning market entry or expansion strategies.

Recent Developments

Recent developments in the Paroxysmal Nocturnal Hemoglobinuria market include several promising advancements:

Approval of New Therapies: In recent years, the FDA has approved new therapies like ravulizumab, offering extended dosing intervals and improved patient compliance compared to existing treatments.

Launch of Biosimilars: Several companies have announced the development of biosimilars for eculizumab, aiming to provide more cost-effective treatment options and expand access.

Advancements in Diagnostic Techniques: Improved diagnostic techniques, including flow cytometry and genetic testing, are helping clinicians detect PNH earlier and with greater accuracy.

Emergence of Complement Inhibitors: New complement inhibitors targeting different components of the complement cascade, such as Factor D and Factor B inhibitors, are showing promising results in clinical trials.

Partnerships and Collaborations: Pharmaceutical companies are increasingly forming strategic partnerships to accelerate drug development and expand their product offerings in the PNH market.

The outlook for Paroxysmal Nocturnal Hemoglobinuria remains promising, with ongoing innovations and an expanding market driven by improved diagnostic capabilities and novel treatment options.

Related reports:

· Retail Pharmacy Market

· Autism Spectrum Disorder Market

· Surrogacy Market

· Livestock Monitoring Market

· Lupin Market

Top of Form

Bottom of Form

0 notes

bommagoni · 8 months ago

Text

Rare Hematology Disorders Market Size, Share, Forecast-2030

#Rare Hematology Disorders Market

0 notes

alliedanalytics · 3 years ago

Text

Positive impact of covid-19 on Rare hematology disorders market

Rare hematology disorders market Outlook - 2027

Rare blood diseases include sickle cell disease, beta thalassemia, follicular lymphoma, multiple myeloma, antiphospholipid syndrome, thrombotic thrombocytopenic purpura, and others. Blood develops from hematopoietic stem cells (HSC) and formation takes place in the bone marrow through a sequence of the regulated process known as hematopoiesis. Blood contains component such as plasma, RBS, WBC, and platelets. Blood disorders include bleeding disorders such as hemophilia, blood clots; blood cancers (leukemia, lymphoma, and myeloma). When the normal process of the blood development fails, abnormal blood cell type is produced, which causes blood cancer and other blood disorders. The rare hematological disease includes anemia-type red blood cell conditions, white blood cell dysfunctions, immuno-disorders and other platelet-based abnormalities. The other hemoglobinopathies are also on the rise due to increasing immigration of carriers from underdeveloped nations to developed regions of the world. The rare blood disorders are difficult to diagnose and treat.

The coronavirus COVID-19 has affected 213 countries and territories around the world. COVID-19 has created new challenges that are requiring manufacturers to innovate at speeds they never have before. Supply chain disruptions, social distancing on high-touch assembly lines, limited ability to travel, and the need for oversight add significant complexity to today’s processes. The outbreak of coronavirus disease 2019 (COVID-19) has created a global health crisis that has had a deep impact on the manufacturing market there is a shortage in supply of raw materials from Chinese manufacturers which has resulted in a severe demand-supply gap. The manufacturers are further expected to be stranded on raw material orders owing to the logistics industry being significantly impacted due to lockdown amid COVID-19. This has all affected the market adversely causing a slowdown in the rare hematology disorders market due to shortage of supply and manufacturing drugs.

Download Sample Report at: https://www.alliedmarketresearch.com/request-sample/11306

Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact analysis:

Drivers:

Increased prevalence:

Rare diseases comprise a growing public health priority, as they affect above 300 million people globally and they are difficult to diagnose and treat. There is a pressing need for better ways to detect and diagnose rare diseases, as well as to provide companion diagnostics for therapy guidance, clinical trials enrollment and therapy monitoring applications. In the U.S., the condition is considered as rare when it affects less than 200,000 people in the United States or prevalence of 5 per 10,000. In Europe, 5 in 10,000 citizens are considered as rare diseases. According to Eurordis (European organization of rare diseases), there are approximately 6000 to 8000 rare diseases. Around 15 million people across the globe suffer from thalassemic disorders and nearly 1.5% of the world population is estimated to be a carrier of β-thalassemia. Rare hematology disorder treatment among the geriatric population base will show boast in future. An overall occurrence of anemia ranges from 10% to 24% among the senior adults. As the age of patient increases, the need for hematology disorder care also increases. Thus, the growing population of geriatric age group will increase the chances of developing rare blood disorders among adults, thereby boosting the demand for hematology disorder treatment in the forecast period.

Development of new therapies:

Global Blood Therapeutics (GBT) is developing biologics for the treatment of sickle cell disease. The company lead candidate, voxelotor (GBT440) is in Phase 3 trials and being investigated for the treatment of sickle cell disease. The candidate is a hemoglobin S polymerization inhibitor and its mechanism of action is modulation hemoglobin affinity for oxygen. FDA has granted has breakthrough therapy, fast track, orphan drug and rare pediatric disease designations to Vozelotor. Imara is developing novel therapeutics for patients suffering from sickle cell disease and other hemoglobinopathies. Sickle cell disease is a rare, genetic blood disease that causes red blood cells to sickle and become damaged, activating immune cells and blocking blood flow in capillaries, injuring many organs and causing daily pain. Its lead candidate is IMR-687, a small molecule inhibitor of phosphodiesterase-9 (PDE9i) for the treatment of sickle cell disease. Launched in April 2016 by orphan drug accelerator Cydan Development. Cyclerion is involved in developing therapies for treating sickle cell disease (SCD) and diabetic nephropathy. They are focused on the nitric oxide-cyclic guanosine monophosphate (cGMP) signaling pathway. Their lead candidate, Olinciguat, which is a vascular guanylate cyclase agonist. The candidate is in phase II clinical trial. They have granted Orphan Drug Designation for SCD by the U.S. Food and Drug Administration. The development of such therapies and treatment for the diseases will drive the Rare hematology disorders market growth.

Restrains:

High cost of treatment and late detection in developing countries will prove as the restrain for market growth.

Key benefits of the report:

This study presents the analytical depiction of the global rare hematology disorders industry along with the current trends and future estimations to determine the imminent investment pockets.

The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global rare hematology disorders market share.

The current market is quantitatively analyzed from 2020 to 2027 to highlight the global rare hematology disorders market growth scenario.

Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.

The report provides a detailed global rare hematology disorders market analysis based on competitive intensity and how the competition will take shape in coming years.

Read more: https://www.alliedmarketresearch.com/rare-hematology-disorders-market-A10941

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:

David Correa 5933 NE Win Sivers Drive #205, Portland, OR 97220 United States USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141 UK: +44-845-528-1300 Hong Kong: +852-301-84916 India (Pune): +91-20-66346060 Fax: +1(855)550-5975 [email protected] Web:https://www.alliedmarketresearch.com Follow Us on LinkedIn:https://www.linkedin.com/company/allied-market-research

#Rare hematology disorders market size #Rare hematology disorders market growth #Rare hematology disorders market trends

0 notes

don-lichterman · 2 years ago

Text

Rare Hematology Disorders Market to Witness Huge Growth by 2030

Rare Hematology Disorders Market PORTLAND, OR, UNITED STATE, November 4, 2022 /EINPresswire.com/ — Allied Market Research added new research on Global Rare Hematology Disorders Market– Global Opportunity Analysis and Industry Forecast, 2022–2030. The Rare Hematology Disorders market explores comprehensive study on various segments like size, share, development, innovation, sales and overall…

View On WordPress

0 notes

vicky8588 · 3 years ago

Text

Rare Haematology Market Size Share and Industry Outlook to 2028

Global Rare Haematology Market is segmented By Product Class (Recombinant factor, Plasma-derived factors, Extended Half-Life), By Indication (Hemophilia A, Hemophilia A with Inhibitors, Hemophilia B, Acquired Hemophilia A, von Willebrand disease), By Patient Age-Group (Pediatrics (0-17), Adults (18+)), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2021-2028

Market Overview

The Global Rare Haematology Market is expected to grow at a high CAGR during the forecasting period (2021-2028).

Rare hematological diseases fall into many subcategories, including anemia-type red blood cell conditions, white blood cell dysfunctions associated with various malignancies, immuno-disorders, platelet-based abnormalities that affect coagulation, and plasma-based issues (such as hemophilia A and B, von Willebrand disease).

Globally, the Rare Hematology market was estimated at USD 10 billion in 2015 and is expected to reach USD 13 billion by 2020. The market is large and growing primarily led by Hemophilia.

Download Free Sample: https://www.datamintelligence.com/download-sample/rare-haematology-market

Market Growth and Trends

The global incidence of hemophilia is not well known, but it is estimated that more than 400,000 people are living with hemophilia A and B.

Approximately 75% of people with hemophilia around the globe still receive inadequate treatment or have no access to treatment. This presents a tremendous market opportunity, thus driving market growth in the future.

On the contrary, the inadequacy of data due to limited support from disease-specific foundations inhibits market growth.

However, there is still a substantial unmet need for new therapies that require significantly less frequent infusions and do not promote inhibitor formation.

Market Segmentation

Global Rare Hematology market report segments the market by product class, by indication, by age, and by region.

Based on product class, the market is classified into Recombinant factors, Plasma-derived factors, and Extended Half-Life clotting factors.

The recombinant factors segment is projected to witness the highest revenue growth, garnering more than USD 4 billion by 2022.

Based on the indication, the market is segmented into Hemophilia A, Hemophilia A with Inhibitors, Hemophilia B, Acquired Hemophilia A, and von Willebrand disease.

The market is led by Hemophilia A segment.

Based on the patient age group, the market is segmented into adults (18+) and pediatrics (0-17).

Adults account for 75% of the market.

Geographically, the market is segmented into five major regions, namely North America, South America, Europe, Asia Pacific, and RoW.

Globally North America is the largest market for Rare Hematology Treatment with the majority of demand arising from the US.

The US hemophilia drug market, which serves about 20,000 patients, is worth USD 4 billion a year.

Market Scope of the Report

By Product Class

· Recombinant factor

· Plasma-derived factors

· Extended Half-Life

By Indication

· Hemophilia A

· Hemophilia A with Inhibitors

· Hemophilia B

· Acquired Hemophilia A

· von Willebrand disease

By Patient Age-group

· Pediatrics (0-17)

· Adults (18+)

By Region

· Asia Pacific (China, Japan, India, Australia, Rest of Asia Pacific)

· Europe (Germany, France, The UK, Italy, Spain, Rest of Europe)

· North America (The USA, Canada, Mexico)

· South America (Brazil, Argentina, Rest of South America)

· Rest of the World

The report also profiles the following companies in the Rare Hematology Treatment market – Biogen Inc., Shire plc, Bayer Healthcare AG, Novo Nordisk A/S, Pfizer Inc., CSL Behring LLC, Celgene Corporation, Amgen Inc. and others.

Why purchase the report?

Visualize the composition of the Rare Hematology market across each indication, regarding type and treatment options, highlighting the critical commercial assets and players.

Identify commercial opportunities in the Rare Hematology market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of the market – level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for critical products of all major market players

Target Audience

Who are the key vendors in the global hematology analyzers market?

· Equipment Suppliers/ Buyers

· Service Providers/ Buyers

· Industry Investors/Investment Bankers

· Education & Research Institutes

· Research Professionals

· Emerging Companies

· Manufacturers

· Trending Topics

· Sickle Cell Treatment Market

· Serum Separation Gel Market

· Allogeneic Stem Cells Market

About Us

DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year, we have secured more than 100 unique customers from established organizations all over the world.

For more information:

Sai Kiran

Sales Manager at DataM Intelligence

Email: [email protected]

Tel: +1 877 441 4866

Website: www.datamintelligence.com

#hematology

0 notes

industry365 · 3 years ago

Text

Rare Disease Genetic Testing Market Is Expected To Reach New Growth Revenues During 2021-2028

The global rare disease genetic testing market size is expected to reach USD 1.8 Billion by 2027 according to a new study by Polaris Market Research. The report “Rare Disease Genetic Testing Market Share, Size, Trends, Industry Analysis Report, By Disease Type (Neurological Disorders, Immunological Disorders, Hematology Ailments, Endocrine & Metabolism Disorders, Cancer, Musculoskeletal Disorders, Cardiovascular Disorders, Dermatology Disorders, Others); By Technology; By Specialty; By End-Use; By Regions; Segment Forecast, 2020 – 2027” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The growing need for on-time diagnosis of uncommon disorders, rising prevalence of rare disorders, innovations in genomic testing, and the focused approach of the market player’s in cost-effective treatments are the key factors responsible for market growth. Moreover, government-sponsored schemes are also expected to positively impact the market. In February 2020, the government of India announced financial assistance of INR 15 lacs to the patients suffering from uncommon ailments under the Rashtriya Arogaya Nidhi scheme for a one-time treatment.

The global rare disease genetic testing industry is fragmented based on disease type, technology, specialty, end-use, and region. In terms of disease type, the market is segmented into neurological disorders, immunological disorders, hematology illnesses, endocrine & metabolism ailments, cancer, musculoskeletal disorders, cardiovascular disorders, dermatology illnesses, and others.

Based on technology, the rare disease genetic testing industry is further bifurcated into next-generation sequencing, array technology, PCR-based testing, FISH, sanger sequencing, and karyotyping. Based on specialty, the rare disease genetic testing industry is further bifurcated into molecular, chromosomal, and biochemical genomic tests. Based on end-use, the rare disease genomic testing industry is further bifurcated into research laboratories & CROs, hospitals & clinics, and diagnostic laboratories.

Download sample: https://www.polarismarketresearch.com/industry-analysis/rare-disease-genetic-testing-market/request-for-sample

Segment Highlights

Neurological ailments accounted for the largest revenue share in 2019 on account of the increasing prevalence of neurologic disorders across the globe and presence of numerous testing techniques

Based on technology, the next generation sequencing segment is projected to constitute almost half of the market in 2027. The usage of the technology in whole genome sequencing is the key factor responsible for its segment’s growth.

Molecular tests are expected to account for the highest revenue share by the end of 2027. The availability of advanced technologies and ability to test ultra-rare disorders is expected to drive market growth.

Research laboratories & CROs accounted for the largest revenue share in 2019 owing to the increasing number of tests and growing occurrence of rare disorders across the developed economies

List of Key Players

Strand Life Sciences

Myriad Genetics

Quest Diagnostics Inc.

Centogene N.V.

Invitae Corporation

Baylor Genetics

Ambry Genetics

Macrogen, Inc.

Opko Health, Inc.

Color Genomics, Inc.

Health Network Laboratories

Preventiongenetics, Progenity, Inc.

Fulgent Genetics Inc.

Others

Get Discount offer: https://www.polarismarketresearch.com/industry-analysis/rare-disease-genetic-testing-market/request-for-discount-pricing

Polaris Market Research has segmented the rare disease genetic testing market report on the basis of disease type, technology, specialty, end-use, and region

Rare Disease Genetic Testing, Disease Type Outlook (Revenue – USD Million, 2016 – 2027)

Neurological Disorders

Immunological Disorders

Hematology Ailments

Endocrine & Metabolism Disorders

Cancer

Musculoskeletal Disorders

Cardiovascular Disorders

Dermatology Disorders

Others

Rare Disease Genetic Testing, Technology Outlook (Revenue – USD Million, 2016 – 2027)

Whole Exome Sequencing

Whole Genome Sequencing

Rare Disease Genetic Testing, Specialty Outlook (Revenue – USD Million, 2016 – 2027)

Molecular Genetic Tests

Chromosomal Genetic Tests

Biochemical Genetic Tests

Rare Disease Genetic Testing, Technology Outlook (Revenue – USD Million, 2016 – 2027)

Research Laboratories & CROs

Hospitals & Clinics

Diagnostic Laboratories

Rare Disease Genetic Testing, Regional Outlook (Revenue – USD Million, 2016 – 2027)

U.S.

Canada

France

Germany

Italy

Spain

Netherlands

Austria

China

India

Japan

Malaysia

South Korea

Indonesia

Mexico

Brazil

Argentina

UAE

Saudi Arabia

Israel

South Africa

Buy Now: https://www.polarismarketresearch.com/checkouts/7391

0 notes

healthcare-market · 3 years ago

Text

Recombinant Plasma Protein Therapeutics Market Trends and Forecast up to 2026

Transparency Market Research (TMR) has published a new report titled, “Recombinant Plasma Protein Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”. According to the report, the global recombinant plasma protein therapeutics market was valued at US$ 8.2 Bn in 2017. It is anticipated expand at a CAGR of 8.6% from 2018 to 2026. Replacement of plasma derived proteins by recombinant plasma products, increase in the number of products launched, and rise in the demand for novel therapies of hemophilia treatment are anticipated to drive the market.

Request a PDF Sample - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=62010

Rising Number of Regulatory Approvals to Drive Market

There has been an increase in the number of regulatory approvals in the last three years that have increased the availability of various options for patients with rare diseases such as hemophilia and other bleeding disorders. These approvals enabled companies to expand their product portfolios and gain competitive advantage. For instance, in September 2017, Ministry of Health, Labour and Welfare, Japan, approved CSL Behrings AFSTYLA, a recombinant factor VIII indicated for the treatment of hemophilia A. AFSTYLA has been also approved in the U.S., Canada, and Switzerland. In April 2018, Shire received Food and Drug Administration (FDA) approval for VONVENDI recombinant von Willebrand factor, indicated for perioperative management of bleeding in patients with von Willebrand disease (VWD). In July 2018, Bayer AG announced the approval for Kovaltry, recombinant factor VIII from the regulatory authorities in China, indicated for the treatment of hemophilia A.

Request a PDF Brochure - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=62010

Asia Pacific offering Numerous Growth Opportunities to the Market

In Asia Pacific, increase in the number of cases of rare hematology disorders, rise in adoption of recombinant DNA technology for therapeutic use, and surge in R&D expenditure by pharmaceutical & biotechnology companies are anticipated to drive the market. Additionally, the demand for third-generation recombinant coagulation factors is increasing in Japan and China, which further creates growth opportunities in the market. Government and non-government organizations are presently taking efforts to increase awareness about hemophilia A and hemophilia B, helping the general population to understand the cases, diagnosis, and treatment methods for such rare diseases. Countries such as China, Japan, Australia, and New Zealand are currently switching to recombinant plasma therapies as standard for hemophilia A treatment, with regulatory authorities. According to Hemophilia Foundation Australia, 80% of patients with bleeding disorders are treated with recombinant coagulation factors. Therefore, increase in the use of recombinant therapies for hemophilia treatment is expected to drive the market during the forecast period.

Request for Analysis of COVID19 Impact on Recombinant Plasma Protein Therapeutics Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=62010

Strategic Approaches and Increasing Focus on R&D by Market Players

The report also provides profiles of leading players operating in the global recombinant plasma protein therapeutics market. These include CSL Limited, Shire (Takeda Pharmaceutical Company Limited), Octapharma, Novo Nordisk A/S, Bayer AG, Bioverativ Therapeutics, Inc. (Sanofi), Aptevo Therapeutics, Pharming Group NV, and Pfizer Inc.

Buy now Recombinant Plasma Protein Therapeutics Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=62010&ltype=S

New product launch, acquisition, geographical expansion, collaborations, and distribution agreements enable these companies to expand their presence in the global market. In January 2019, Shire was acquired by Takeda Pharmaceutical Company Limited, a pharmaceutical company based in Japan. With this acquisition, Takeda Pharmaceutical Company Limited is expected to strengthen its geographical presence. In January 2018, Sanofi, a leading pharmaceutical company, acquired Bioverativ Therapeutics Inc., which operated as a part of Sanofi Genzyme. Other market players have also undertaken numerous initiatives to expand their business in emerging markets. Leading market players are also focusing on increasing their customer base in countries in Asia Pacific such as China, Japan, and Australia. Market players are also supporting several campaigns for increasing awareness about hematological disorders and availability of treatment options such as recombinant plasma proteins and the advantages offered by these products.

More Trending Reports by Transparency Market Research:

https://www.prnewswire.com/news-releases/global-customized-procedure-trays-market-to-grow-as-the-medical-industry-acquires-research-excellence-says-tmr-301210766.html

https://www.prnewswire.com/news-releases/technological-strides-in-bladder-scanners-market-help-clinicians-advance-care-for-patients-with-urinary-tract-infections-valuation-to-touch-mark-of-us-210-0-mn-by-2026-tmr-301213972.html

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research, 90 Sate Street, Suite 700, Albany, NY 12207 Tel: +1-518-618-1030 USA - Canada Toll Free: 866-552-3453 Website: https://www.transparencymarketresearch.com/

0 notes

karishmamulani · 3 years ago

Text

Rare Disease Genetic Testing Market Global Industry Analysis By Trends, Future Demands, Growth Factors 2028

View On WordPress

#Rare Disease Genetic Testing #Rare Disease Genetic Testing Market #Rare Disease Genetic Testing Market Share #Rare Disease Genetic Testing Market Size

0 notes

decisionforsight · 3 years ago

Text

Global Protein Therapeutics Market

Global Protein Therapeutics Market Size, Share, Growth, Industry Trends and Forecast 2020-2030

The Global Protein Therapeutics Market size valued USD 176884.4 million in 2020, and anticipated to reach at USD 298842.4 million up to 2030 to grow with the CAGR of 6.0% in forecast period.Therapeutics protein are the protein which are engineered in laboratory for pharmaceutical use, which affect the covalent bond which are albumin and enzyme that help to heal from the dieses. Therapeutics protein are the important class of medicine, which help to treat different dieses like infectious dieses like infectious dieses, cancer, and others, and have potential to improve human health. Therapeutics proteins are highly specific and complex set of function. This get well immune response and well tolerate by human body. This is an effective treatment without gene therapy. There are total 239 therapeutic protein approved for clinical use by US – FDA out of them monoclonal antibiotics has largest share in the market followed by insulin, erithro protein, fusion protein, interferon, human growth hormone and others. These are helpful for the individuals whose body cannot produce essential protein naturally. It is useful for genetic, life threating, and rare dieses. According to National Cancer Institute 38.4% of global people diagnosed by the cancer in some point of their life, 3.1% of global folk fighting with the hypertension, and 8.8% of globe folk has diabetes that they can cure by using protein therapeutics.

Download Sample Copy of the Report to understand the structure of the complete report (Including Full TOC, Table & Figures) @ https://www.decisionforesight.com/request-sample/DFS020284

Market Dynamics and Factors:

Increasing prevalence of chronic diseases like cancer, and plasma derived market are the main driver of the global protein therapeutics market. Moreover, increasing awareness about protein therapeutics, instead of surgery protein therapeutics with minimum side effect, and increasing level of acceptable in user, are the factor that help to boost the protein therapeutics market. Stringent laws and regulations in some region, and high cost of product may hamper the protein therapeutics market growth. Rising global prevalence of different diabetes led to significant growth in development in the market.

Market Segmentation:

Global Protein Therapeutics Market – By Product

Monoclonal Antibodies

Insulin

Fusion Protein

Erythropoietin

Interferon

Human Growth Hormone

Follicle Stimulating Hormone

Global Protein Therapeutics Market – By Application

Metabolic Disorders

Immunologic Disorders

Hematological Disorders

Cancer

Hormonal Disorders

Genetic Disorders

Others

Global Protein Therapeutics Market– By Region

North America

USA

Mexico

Canada

Europe

UK.

Rest of Europe

Italy

Germany

France

Asia-Pacific

Japan

Rest of Asia-Pacific

Australia

India

China

RoW

Latin America

Africa

Middle East

New Business Strategies, Challenges & Policies are mentioned in Table of Content, Request TOC at @ https://www.decisionforesight.com/toc-request/DFS020284

Geographic Scenario:

North America dominating the global protein therapeutics market, as the development pharmaceuticals infrastructure, and development in R&D sector. Moreover, technological advancement in this region help protein therapeutics market to grow. Asia Pacific is the highest growing market, as rise in protein therapeutics application and increasing awareness about it in this region. Developing the R&D sector and pharmaceutical sector in this region help protein therapeutics market growth.

Competitive Scenario:

The key player in, the global protein therapeutics industry are Eli Lilly and Company, Abbott Laboratories, Amgen Inc., Baxter International Inc., Novo Nordisk A/S, Pfizer Inc., F. Hoffmann-La Roche Ltd., Novo Nordisk A/S, Pfizer Inc., Johnson & Johnson, Merck & Co., Inc., Sanofi., Biogen, Inc., CSL Behring, Genentech, Inc., and others.

Connect to Analyst @ https://www.decisionforesight.com/speak-analyst/DFS020284

How will this Market Intelligence Report Benefit You?

The report offers statistical data in terms of value (US$) as well as Volume (units) till 2030.

Exclusive insight into the key trends affecting the Global Protein Therapeutics industry, although key threats, opportunities and disruptive technologies that could shape the Global Protein Therapeutics Market supply and demand.

The report tracks the leading market players that will shape and impact the Global Protein Therapeutics Market most.

The data analysis present in the Global Protein Therapeutics Market report is based on the combination of both primary and secondary resources.

The report helps you to understand the real effects of key market drivers or retainers on Global Protein Therapeutics Market business.

The 2021 Annual Global Protein Therapeutics Market offers:

100+ charts exploring and analysing the Global Protein Therapeutics Market from critical angles including retail forecasts, consumer demand, production and more

15+ profiles of top producing states, with highlights of market conditions and retail trends

Regulatory outlook, best practices, and future considerations for manufacturers and industry players seeking to meet consumer demand

Benchmark wholesale prices, market position, plus prices for raw materials involved in Global Protein Therapeutics Market type

Buy This Premium Research Report@ https://www.decisionforesight.com/checkout/DFS020284

About Us:

Decision Foresight is a market research organization known for its reliable and genuine content, market estimation and the best analysis which is designed to deliver state-of-the-art quality syndicate reports to our customers. Apart from syndicate reports, you will find the best market insights, strategies that will help in taking better business decisions on subjects that may require you to develop and grow your business-like health, science, technology and many more. At Decision Foresight, we truly believe in disseminating the right piece of knowledge to a large section of the audience and cover the in-depth insights of market leaders across various verticals and horizontals.

Contact:

Email: [email protected]

For Latest Update Follow Us:

https://www.facebook.com/Decision-Foresight-110793387201935

https://twitter.com/DecisionFs

https://www.linkedin.com/company/decision-foresight/

0 notes

blogkdmi-blog · 6 years ago

Text

Global In Vitro Diagnostics (IVD) Market Size, Share, Growth, Trends and Forecast 2018 - 2025

The global in vitro diagnostics (IVD) market was valued at $64,479 million in 2017, and is estimated to reach at $93,614 million by 2025, registering a CAGR of 4.8% from 2018 to 2025.

In vitro diagnostic (IVD) is a technique in which medical devices and reagents are used to examine specimens such as blood, urine, stool, tissues, and other body fluids, which are derived from the human body to detect diseases, conditions, and infections. The tests can be performed in stand-alone laboratory, hospital-based laboratory, and point of care. Some of the significant technologies incorporated in IVD include polymerase chain reaction (PCR), microarray techniques, sequencing technology, and mass spectrometry, which are used for test sample preparation. Incessant innovations in IVD product type design and technology have encouraged doctors and researchers to shift their focus from traditional diagnostic methods to personalized medicines.

Request for Sample @ https://www.kdmarketinsights.com/sample/4319

Rise in need for IVD testing arises due to increase in incidences of chronic and infectious diseases and growth in geriatric population prone to immunological disorders. Moreover, advancements in personalized medicines and widespread knowledge of rare diseases are expected to boost the growth of the global IVD market. In addition, increase in incidences of colorectal cancer, neurological disorders, and gynecological diseases are anticipated to boost the adoption of IVD devices and reagents. On the contrary, stringent government regulations and unfavorable reimbursement policies are expected to restrain the growth of the global market.

Based on techniques, the market is segmented into immunodiagnostics, hematology, molecular diagnostics, tissue diagnostics, clinical chemistry, and other IVD techniques. The immunodiagnostics is further segmented into enzyme-linked immunosorbent assay (ELISA), rapid tests, enzyme-linked immunospot (ELISPOT), radioimmunoassay (RIA), and western blot. The ELISA segment is further classified into chemiluminescence immunoassay (CLIA), fluorescence immunoassay (FIA), and colorimetric immunoassay (CI). Molecular diagnostics segment is further divided into polymerase chain reaction (PCR), isothermal nucleic acid amplification technology (INAAT), hybridization, DNA diagnostics, microarrays, and others. Similarly, clinical chemistry segment is categorized into basic metabolic panel, liver panel, lipid profile, thyroid function panel, renal profile, electrolyte panel, and specialty chemicals.

By application, the market is classified into infectious diseases, cancer, cardiac diseases, immune system disorders, nephrological diseases, gastrointestinal diseases, and other indications. Based on end user, it is divided into hospitals, academic & medical schools, point of care testing, and others. Based on region, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Key players profiled in the report include Abbott Laboratories; Becton, Dickinson and Company; bioMÃ©rieux SA, Bio-Rad Laboratories, Inc.; Danaher Corporation (Beckman Coulter, Inc.); F. Hoffmann-La Roche Ltd.; Johnson & Johnson; QIAGEN N.V.; Sysmex Corporation; and Thermo Fisher Scientific, Inc.

Key Benefits for IVD Market:

- The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.

- It offers a quantitative analysis from 2017 to 2025, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.

- A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.

- The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.

IVD Key Market Segments:

By Product Type

- Reagents

- Instruments

- Software & Services

By Techniques

- Immunodiagnostics

- - Enzyme-Linked Immunosorbent Assay (ELISA)

- - - - Chemiluminescence Immunoassays (CLIAS)

- - - - Fluorescence Immunoassays (FIAS)

- - - - Colorimetric Immunoassays (CIS)

- - Rapid Tests

- - Enzyme-Linked ImmunoSpot Assays (ELISPOT)

- - Radioimmunoassay

- - Western Blot

- - Hematology

- Molecular Diagnostics

- - Polymerase Chain Reaction (PCR)

- - Isothermal Nucleic Acid Amplification Technology (INAAT)

- - Hybridization

- - DNA Diagnostics

- - Microarrays

- - Others

- Tissue Diagnostics

- Clinical Chemistry

- - Basic Metabolic Panel

- - Liver Panel

- - Lipid Profile

- - Thyroid Function Panel

- - Renal Profile

- - Electrolyte Panel

- - Specialty Chemicals

- Other IVD Techniques

By End User

- Standalone Laboratory

- Hospitals

- Academic & Medical Schools

- Point of Care Testing

- Others

By Region

North America

- U.S.

- Canada

- Mexico

Europe

- Germany

- France

- UK

- Italy

- Spain

- Rest of Europe

Asia-Pacific

- Japan

- China

- Australia

- India

- South Korea

- Rest of Asia-Pacific

LAMEA

- Brazil

- Saudi Arabia

- South Africa

- Rest of LAMEA

List Of Key Players Profiled in the Report

- Abbott Laboratories

- Becton, Dickinson and Company

- bioMrieux SA

- Bio-Rad Laboratories, Inc.

- Danaher Corporation (Beckman Coulter, Inc.)

- F. Hoffmann-La Roche Ltd.

- Johnson & Johnson

- QIAGEN N.V.

- Sysmex Corporation

- Thermo Fisher Scientific, Inc.

List Of Other Players in the Value Chain (These players are not profiled in the report. The same will be included on request)

- Illumina, Inc.

- Luminex Corporation.

- Siemens Healthcare GmbH.

Browse Full Report With TOC@ https://www.kdmarketinsights.com/product/in-vitro-diagnostics-ivd-market-amrr

Table of Contents@

CHAPTER 1: INTRODUCTION

1.1. Report description

1.2. Key benefits for stakeholders

1.3. Key market segments

1.3.1. List of key players profiled in the report

1.4. Research methodology

1.4.1. Secondary research

1.4.2. Primary research

1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings of the study

2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope

3.2. Key findings

3.2.1. Top investment pockets

3.3. Top winning strategies, 2017

3.4. Top player positioning, 2017

3.5. Porters five forces analysis

3.6. Market dynamics

3.6.1. Drivers

3.6.1.1. Increase in incidence of chronic and infectious diseases

3.6.1.2. Technological advancements in IVD

3.6.1.3. Emergence of minimal invasive technologies

3.6.1.4. Increasing government expenditures on healthcare

3.6.1.5. Increase in popularity of personalized medicine approach

3.6.2. Restraint

3.6.2.1. Unclear reimbursement policies

3.6.2.2. Stringent regulatory policies

3.6.3. Opportunities

3.6.3.1. Potential opportunities for outsourcing

3.6.3.2. Convergence of new technologies

3.6.4. Impact Analyses

CHAPTER 4: IN-VITRO DIAGNOSTICS MARKET, BY PRODUCT TYPE

4.1. Overview

4.1.1. Market size and forecast

4.2. Reagents

4.2.1. Key market trends, growth factors, and opportunities

4.2.2. Market size and forecast, by region

4.2.3. Market analysis, by country

4.3. Instruments

4.3.1. Key market trends, growth factors, and opportunities

4.3.2. Market size and forecast, by region

4.3.3. Market analysis, by country

4.4. Software & Services

4.4.1. Key market trends, growth factors, and opportunities

4.4.2. Market size and forecast, by region

4.4.3. Market analysis, by country

Continue…

Check for Discount@ https://www.kdmarketinsights.com/discount/4319

About KD Market Insights

KD Market Insights has come with the idea of helping business by intelligent decision making and thorough understanding of the industry. We offer a comprehensive database of syndicated research, customized reports as well as consulting services to help a business grow in their respective domain. At KD Market Insights, we offer our client a deep Market research reports accompanied by business consulting services that can help them to reach on top of the corporate world. Our customized reports are built by keeping all factors of the industry in mind.

150 State street, 3rd Floor,

Albany, New York

United states (12207)

Telephone: +1-518-300-1215

Email: - [email protected]

Website: - www.kdmarketinsights.com

#In Vitro Diagnostics (IVD) Market #In Vitro Diagnostics (IVD) Market Size #In Vitro Diagnostics (IVD) Market Share #In Vitro Diagnostics (IVD) Market Growth

0 notes

myabhijitr · 6 years ago

Text

Newborn Screening Market - Global Industry Size, Share, Analysis By 2018-2026

Newborn screening tests look for developmental, metabolic, and genetic disorders in infants. It allows steps to be taken before development of symptoms. Although, majority of these illnesses are very rare, they can be treated with early diagnosis. Newborn screening includes over 30 conditions and illnesses. Increasing awareness among parents for disease screening is a major factor driving newborn screening market growth. Furthermore, various government and non-government organizations are actively focused on offering better fetal and maternal care. For instance, in June 2018, the American Society of Hematology (ASH) led a campaign to fight sickle cell disease in Africa and urged governments, particularly in sub-Saharan Africa, to invest in newborn screening of the disease.

Get Exclusive Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/2192

Novel treatments, biomarkers, and technologies are expected to enable various diseases to be considered as potential candidates to be included in New Born Screening (NBS) programs. For instance, new treatments such as Hematopoietic Stem Cell Transplant (HSCT), Enzyme Replacement Therapy (ERT), and gene therapy and new pharmacological drugs have allowed autoimmune diseases to be considered as potential candidates to be included in NBS programs.

Market Dynamics

Increasing number of newborn screenings, owing to rising awareness among parents and governments is expected to drive the newborn screening market growth. According to the Centers for Disease Control and Prevention (CDC) 2017, four million infants in the U.S. are routinely screened, using a few drops of blood from their heel, for certain endocrine, genetic, and metabolic disorders. The infants are also tested for hearing loss and Critical Congenital Heart Defects (CCHDs) prior to discharge from a hospital or birth center.

Furthermore, increasing incidence of hospital acquired diseases create an acute need for newborn screening. For instance, according to the Center for Disease Control and Prevention (CDC), in 2011, around one in every 25 infants was infected with at least one hospital acquired infections.

Government initiatives to support screening of newborns is also a major factor driving the newborn screening market. For instance, CDC is working to harness the latest advances in science and technology so that more disorders can be identified accurately and treated quickly. In 2005, CDC established the Newborn Screening Translation Research Initiative (NSTRI) with the CDC Foundation. NSTRI works with corporate, academic, and foundation partners to assure the quality of research methods during both pilot studies and routine screening.

Download PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/2192

Key players operating in the global newborn screening market include, Agilent Technologies, AB SCIEX, Bio-Rad Laboratories, Covidien PLC, GE Life Sciences, Masimo Corporation, Natus Medical Inc., PerkinElmer Inc., and ZenTech S.A.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

#Newborn screening Market #Newborn screening Market size #Newborn screening Market analysis

0 notes

sapanas · 4 years ago

Text

COVID 19 Impact: Plasma Fractionation Market Share, Growth By Top Company, Application, Driver, Trends & Forecasts By 2023

Market Research Future (MRFR) collected data on several factors including implications of COVID 19 Impact on Plasma Fractionation Market and demographic challenges, showed how it could move forward in the coming years.

Plasma Fractionation Market Major Players:

Key players leading the global plasma fractionation market include Bio Products Laboratory (BPL), Biotest AG, China Biologic Products Holdings, Inc., CSL Limited, Green Cross Corporation, Grifols, S.A., Japan Blood Products Organization, Kedrion S.p.A, LFB group, Sanquin, Shire, Shanghai RAAS and Octapharma AG among others.

Plasma Fractionation Market Analysis

Global plasma fractionation market is growing significantly mainly due to the growing demand for therapies for rare chronic conditions, like autoimmune disorders and hemophilia. Factors such as the increasing number of market players that are increasingly setting up plasma collection centers is a key factor impacting the growth of the market, positively.

The increasing use of plasma in stem cell research, genetic & tissue engineering, biochemistry, and cancer research alongside the growing number of plasma collection centers that are meeting this growing demand are fostering the growth of the market. Moreover, the increasing prevalence of chronic diseases that are prompting the need for effective medicines and treatment methods, hugely, escalate the market on the global platform.

Acknowledging the colossal accruals, the market is garnering steadily, Market Research Future (MRFR), in its recently published study report, asserts that the global plasma fractionation market will further generate exponential accruals by 2023, registering a CAGR of 6.5% throughout the forecast period (2018 -2023). In 2018, the market acquired a valuation of USD 18073 MN.

Get a FREE Sample with Complete TOC By Considering the COVID-19 impact on Global Market @ https://www.marketresearchfuture.com/sample_request/7397

Besides, the rising number of research activities in pharmaceutical manufacturing and bioscience laboratories or research institutes explains the augmented demand for plasma fractionation that is increasing the size of the market. Undoubtedly, improving economic conditions, globally are playing a vital role in propelling market growth, widening access to the quality, and improved health care.

On the other hand, shortages of healthy donors are a key factor impeding the growth of the market. Also, the lack of funding programmes is obstructing the growth of the market, especially in the developing regions.

Nonetheless, the huge support in terms of funding rendered by well-established market players and developed countries is a key factor that would support the growth of the market, filling up the demand and supply gap.

Global Plasma Fractionation Market- Segmentations

For ease of understanding, the analysis has been segmented into four key dynamics:

By Product: Immunoglobulin, Coagulation Factor Concentrates, Albumin, and Protease Inhibitors among others.

By Application: Immunology, Neurology, Hematology, Critical Care, Pulmonology, Rheumatology, and Hemato-oncology among others.

By End-user: Hospitals & Clinics, Clinical Research Laboratories, and Academic Institutes among others.

By Region: North America, Europe, Asia Pacific, and the Rest-of-the-World.

Global Plasma Fractionation Market- Regional Analysis

The North American region, heading with the presence of major market players, dominates the global plasma fractionation market. Factors that are propelling the regional market include the increasing number of R&D activities in the pharmaceutical and biotech industry led by the substantial investments drive the regional market.

The well-developed economy accounts for a key driving force behind the growth of the regional market, allowing adequate funding required for R&D. Besides, the increasing prevalence of various chronic diseases and immunodeficiency disorders foster market growth in the region. The US accounts for the major contributor to the growth of the market, supplying half of the global demand for plasma.

The plasma fractionation market in the European region accounts for the second-largest market, globally. The pervasively growing demand for plasma in the therapies to treat rare chronic conditions, such as autoimmune disorders and hemophilia drive the regional market.

Additionally, the increasing emphasis on R&D in the biotechnology sector led by the rising funding is a dominant driving force behind the market growth in the region. Indeed, the resurging economy in Europe is substantiating the growth of the plasma fractionation market driving the pharma sector.

The Asia Pacific plasma fractionation market has emerged as a profitable market, globally. Factors such as the increasing number of plasma collection centers and research labs are some of the key factors that are defining the market landscape in the region. Also, rapidly improving economic conditions, proliferating pharmaceutical industry and the rapidly developing healthcare technologies in the region provide impetus to the market growth.

Global Plasma Fractionation Market- Competitive Analysis

Highly competitive, the global plasma fractionation market appears to be fragmented with the several large and small players forming a competitive landscape. Leverage to the high demand and the growth potential in the market; these players plan to increase their collected plasma use in the life science environment as well as in other pharma companies.

Key players also emphasis on providing flexible packaging systems offered in multiple formats, including custom configurations to meet customized requirements. They strive to provide such containment and delivery systems that can preserve the physical, chemical, and functional characteristics of the plasma.

They also strive to provide the plasma contain in disposable vessels with advanced surfaces, that will be convenient for the life science researchers. Contracted commercial collectors are not bound to keep collected plasma in the country it is obtained from, and they can redirect it to other buyers as well at the end of the contract term.

Obtain Premium Research Report Details, Considering the impact of COVID-19 @ https://www.marketresearchfuture.com/reports/plasma-fractionation-market-7397

Plasma Fractionation Industry/Innovations/Related News:

March 25, 2019 --– GCAM, Inc., (the US), a plasma collection company, announced the addition of a new plasma collection center in Brownsville, Texas. With the latest additions, GCAM now runs ten plasma donation centers nationwide. Establishing more plasma collection facilities will offer long-term assurances that supply will keep pace with the needs of patients and the plasma collection.

GCAM is a member of South Korea's GC group of companies and runs source plasma centers across the US. And its immediate parent company GCBT owns a state-of-art plasma fractionation facility in Montreal, Quebec. GCAM collects high-quality source plasma for GC Pharma and other plasma fractionators, collecting up to 550,000 liters of source plasma annually.

The company also confirms that two additional plasma collection center will be established this year, helping local economies and bring job opportunities to the local communities.

#Plasma Fractionation Market #Plasma Fractionation Market Size #Plasma Fractionation Market Growth #Plasma Fractionation Market Analysis

0 notes

cool-dangerousheartcollecto-blog · 5 years ago

Text

In Vitro Diagnostics (IVD) Market generated $64,479 million in 2017

KD Market Insights has published a new report on global In Vitro Diagnostics (IVD) Market analysis and forecast 2018-2025. The report comprises of In Vitro Diagnostics (IVD) Market size, Y-o-Y growth analysis, and market dynamics, including growth drivers, restraining factors, opportunities, and trends which are spearheading current nature and future status of the market.

The global in vitro diagnostics (IVD) market was valued at $64,479 million in 2017, and is estimated to reach at $93,614 million by 2025, registering a CAGR of 4.8% from 2018 to 2025.

Request for Sample @ https://www.kdmarketinsights.com/sample/4319

The report segments the market across different categories such as product type, technique, application, end users, and region. Based on product type, the market is segmented into reagents, instruments, and services & software. Based on techniques, the market is segmented into immunodiagnostics, hematology, molecular diagnostics, tissue diagnostics, clinical chemistry, and other IVD techniques. The immunodiagnostics is further segmented into enzyme-linked immunosorbent assay (ELISA), rapid tests, enzyme-linked immunospot (ELISPOT), radioimmunoassay (RIA), and western blot. The ELISA segment is further classified into chemiluminescence immunoassay (CLIA), fluorescence immunoassay (FIA), and colorimetric immunoassay (CI). Molecular diagnostics segment is further divided into polymerase chain reaction (PCR), isothermal nucleic acid amplification technology (INAAT), hybridization, DNA diagnostics, microarrays, and others. Similarly, clinical chemistry segment is categorized into basic metabolic panel, liver panel, lipid profile, thyroid function panel, renal profile, electrolyte panel, and specialty chemicals.

Key Benefits for IVD Market:

- The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets. - It offers a quantitative analysis from 2017 to 2025, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities. - A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities. - The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.

IVD Key Market Segments:

By Product Type

- Reagents - Instruments - Software & Services

By Techniques

- Immunodiagnostics - - Enzyme-Linked Immunosorbent Assay (ELISA) - - - - Chemiluminescence Immunoassays (CLIAS) - - - - Fluorescence Immunoassays (FIAS) - - - - Colorimetric Immunoassays (CIS) - - Rapid Tests - - Enzyme-Linked ImmunoSpot Assays (ELISPOT) - - Radioimmunoassay - - Western Blot - - Hematology - Molecular Diagnostics - - Polymerase Chain Reaction (PCR) - - Isothermal Nucleic Acid Amplification Technology (INAAT) - - Hybridization - - DNA Diagnostics - - Microarrays - - Others - Tissue Diagnostics - Clinical Chemistry - - Basic Metabolic Panel - - Liver Panel - - Lipid Profile - - Thyroid Function Panel - - Renal Profile - - Electrolyte Panel - - Specialty Chemicals - Other IVD Techniques

By End User

- Standalone Laboratory - Hospitals - Academic & Medical Schools - Point of Care Testing - Others

By Region

North America - U.S. - Canada - Mexico Europe - Germany - France - UK - Italy - Spain - Rest of Europe Asia-Pacific - Japan - China - Australia - India - South Korea - Rest of Asia-Pacific LAMEA - Brazil - Saudi Arabia - South Africa - Rest of LAMEA

List Of Key Players Profiled in the Report

- Abbott Laboratories - Becton, Dickinson and Company - bioMrieux SA - Bio-Rad Laboratories, Inc. - Danaher Corporation (Beckman Coulter, Inc.) - F. Hoffmann-La Roche Ltd. - Johnson & Johnson - QIAGEN N.V. - Sysmex Corporation - Thermo Fisher Scientific, Inc.

List Of Other Players in the Value Chain (These players are not profiled in the report. The same will be included on request)

- Illumina, Inc. - Luminex Corporation. - Siemens Healthcare GmbH

Browse Full Report With TOC@ https://www.kdmarketinsights.com/product/in-vitro-diagnostics-ivd-market-amrr

Table of Content

CHAPTER 1: INTRODUCTION

1.1. Report description 1.2. Key benefits for stakeholders 1.3. Key market segments

1.3.1. List of key players profiled in the report

1.4. Research methodology

1.4.1. Secondary research 1.4.2. Primary research 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings of the study 2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope 3.2. Key findings

3.2.1. Top investment pockets

3.3. Top winning strategies, 2017 3.4. Top player positioning, 2017 3.5. Porters five forces analysis 3.6. Market dynamics

3.6.1. Drivers

3.6.1.1. Increase in incidence of chronic and infectious diseases 3.6.1.2. Technological advancements in IVD 3.6.1.3. Emergence of minimal invasive technologies 3.6.1.4. Increasing government expenditures on healthcare 3.6.1.5. Increase in popularity of personalized medicine approach

3.6.2. Restraint

3.6.2.1. Unclear reimbursement policies 3.6.2.2. Stringent regulatory policies

3.6.3. Opportunities

3.6.3.1. Potential opportunities for outsourcing 3.6.3.2. Convergence of new technologies

3.6.4. Impact Analyses

CHAPTER 4: IN-VITRO DIAGNOSTICS MARKET, BY PRODUCT TYPE

4.1. Overview

4.1.1. Market size and forecast

4.2. Reagents

4.2.1. Key market trends, growth factors, and opportunities 4.2.2. Market size and forecast, by region 4.2.3. Market analysis, by country

4.3. Instruments

4.3.1. Key market trends, growth factors, and opportunities 4.3.2. Market size and forecast, by region 4.3.3. Market analysis, by country

4.4. Software & Services

4.4.1. Key market trends, growth factors, and opportunities 4.4.2. Market size and forecast, by region 4.4.3. Market analysis, by country

CHAPTER 5: IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE

5.1. Overview

5.1.1. Market size and forecast

5.2. Immunodiagnostics

5.2.1. Market size and forecast, by type

5.2.1.1. Enzyme-Linked Immunosorbent Assay (ELISA)

5.2.1.1.1. Market size and forecast 5.2.1.1.2. Chemiluminescence Immunoassay (CLIA)

5.2.1.1.2.1. Market size and forecast

5.2.1.1.3. Fluorescence Immunoassay (FIA)

5.2.1.1.3.1. Market size and forecast

5.2.1.1.4. Colorimetric Immunoassay (CI)

5.2.1.1.4.1. Market size and forecast

5.2.1.2. Rapid Tests

5.2.1.2.1. Market size and forecast

5.2.1.3. Enzyme-Linked ImmunoSpot (ELISPOT)

5.2.1.3.1. Market size and forecast

5.2.1.4. Radioimmunoassay (RIA)

5.2.1.4.1. Market size and forecast

5.2.1.5. Western Blot

5.2.1.5.1. Market size and forecast

5.2.2. Market size and forecast, by region 5.2.3. Market analysis, by country

5.3. Hematology

5.3.1. Market size and forecast, by region 5.3.2. Market share analysis, by country

5.4. Molecular Diagnostics

5.4.1. Market size and forecast, by type

5.4.1.1. Polymerize Chain Reaction (PCR)

5.4.1.1.1. Market size and forecast

5.4.1.2. Isothermal Nucleic Acid Technology (INAAT)

5.4.1.2.1. Market size and forecast

5.4.1.3. Hybridization

5.4.1.3.1. Market size and forecast

5.4.1.4. DNA Diagnostics

5.4.1.4.1. Market size and forecast

5.4.1.5. Microarray

5.4.1.5.1. Market size and forecast

5.4.1.6. Others

5.4.1.6.1. Market size and forecast

5.4.2. Market size and forecast, by region 5.4.3. Market share analysis, by country

5.5. Tissue Diagnostics

5.5.1. Market size and forecast, by region 5.5.2. Market share analysis, by country

5.6. Clinical Chemistry

5.6.1. Market size and forecast, by type

5.6.1.1. Basic Metabolic Panel

5.6.1.1.1. Market size and forecast

5.6.1.2. Liver Panel

5.6.1.2.1. Market size and forecast

5.6.1.3. Renal Profile

5.6.1.3.1. Market size and forecast

5.6.1.4. Lipid Profile

5.6.1.4.1. Market size and forecast

5.6.1.5. Thyroid Function Panel

5.6.1.5.1. Market size and forecast

5.6.1.6. Electrolyte Panel

5.6.1.6.1. Market size and forecast

5.6.1.7. Specialty Chemicals

5.6.1.7.1. Market size and forecast

5.6.2. Market size and forecast, by region 5.6.3. Market share analysis, by country

5.7. Others

5.7.1. Market size and forecast, by region 5.7.2. Market share analysis, by country

Continue…

Check for Discount @ https://www.kdmarketinsights.com/discount/4319

About KD Market Insights

KD Market Insights offers a comprehensive database of syndicated research studies, customized reports, and consulting services. These reports are created to help in making smart, instant and crucial decisions based on extensive and in-depth quantitative information, supported by extensive analysis and industry insights.

Our dedicated in-house team ensures the reports satisfy the requirement of the client. We aim at providing value service to our clients. Our reports are backed by extensive industry coverage and is made sure to give importance to the specific needs of our clients. The main idea is to enable our clients to make an informed decision, by keeping them and ourselves up to date with the latest trends in the market.

KD Market Insights

150 State Street, Albany,

New York, USA 12207

+1 (518) 300-1215

Email: [email protected]

Website: www.kdmarketinsights.com

#In Vitro Diagnostics (IVD) Market #In Vitro Diagnostics (IVD) Market Size #In Vitro Diagnostics (IVD) Market Share #In Vitro Diagnostics (IVD) Market News

0 notes

industry365 · 3 years ago

Text

Rare Disease Genetic Testing Market Is Expected To Reach New Growth Revenues During 2021-2028

Download sample: https://www.polarismarketresearch.com/industry-analysis/rare-disease-genetic-testing-market/request-for-sample

Segment Highlights

Neurological ailments accounted for the largest revenue share in 2019 on account of the increasing prevalence of neurologic disorders across the globe and presence of numerous testing techniques

Research laboratories & CROs accounted for the largest revenue share in 2019 owing to the increasing number of tests and growing occurrence of rare disorders across the developed economies

List of Key Players

Strand Life Sciences

Myriad Genetics

Quest Diagnostics Inc.

Centogene N.V.

Invitae Corporation

Baylor Genetics

Ambry Genetics

Macrogen, Inc.

Opko Health, Inc.

Color Genomics, Inc.

Health Network Laboratories

Preventiongenetics, Progenity, Inc.

Fulgent Genetics Inc.

Others

Get Discount offer: https://www.polarismarketresearch.com/industry-analysis/rare-disease-genetic-testing-market/request-for-discount-pricing

Polaris Market Research has segmented the rare disease genetic testing market report on the basis of disease type, technology, specialty, end-use, and region

Rare Disease Genetic Testing, Disease Type Outlook (Revenue – USD Million, 2016 – 2027)

Neurological Disorders

Immunological Disorders

Hematology Ailments

Endocrine & Metabolism Disorders

Cancer

Musculoskeletal Disorders

Cardiovascular Disorders

Dermatology Disorders

Others

Rare Disease Genetic Testing, Technology Outlook (Revenue – USD Million, 2016 – 2027)

Whole Exome Sequencing

Whole Genome Sequencing

Rare Disease Genetic Testing, Specialty Outlook (Revenue – USD Million, 2016 – 2027)

Molecular Genetic Tests

Chromosomal Genetic Tests

Biochemical Genetic Tests

Rare Disease Genetic Testing, Technology Outlook (Revenue – USD Million, 2016 – 2027)

Research Laboratories & CROs

Hospitals & Clinics

Diagnostic Laboratories

Rare Disease Genetic Testing, Regional Outlook (Revenue – USD Million, 2016 – 2027)

U.S.

Canada

France

Germany

Italy

Spain

Netherlands

Austria

China

India

Japan

Malaysia

South Korea

Indonesia

Mexico

Brazil

Argentina

UAE

Saudi Arabia

Israel

South Africa

Buy Now: https://www.polarismarketresearch.com/checkouts/7391

0 notes

srikanthgtbrc-blog · 5 years ago

Text

Drugs for Immunotherapy Market Size, Growth, Drivers, Trends And Forecast

The drugs for immunotherapy market consists of sales of immunotherapy drugs. Immunotherapy drugs help the immune system to fight cancer by stimulating the immune system of the body and generate an immune response aiding the production of antibodies. The high cost of immunotherapy drugs is acting as a restraint on the drugs for immunotherapy market as less number of patients can afford the treatment. Immunotherapy drugs are expensive as drugs are made specifically for each patient and investment costs in the research and development are high.

Browse Drugs for Immunotherapy Global Market Report 2019

https://www.thebusinessresearchcompany.com/report/drugs-for-immunotherapy-global-market-report

The pharmaceutical drugs market consists of sales of goods and related services by entities (organizations, sole traders and partnerships) that manufacture pharmaceutical drugs used to treat various diseases. This industry includes establishments that manufacture drugs such as cardiovascular drugs, gastrointestinal drugs, genito-urinary drugs, hematology drugs and other drugs used to treat cardiovascular diseases, rare genetic disorders, infections, metabolic disorders, cancers, respiratory diseases and others.

Place A Sample Request Of This Report At:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2559&type=smp

List Of Tables

Table 1: Global Historic Market Growth, 2014-2018, $ Billion

Table 2: Global Forecast Market Growth, 2014-2022F, 2025F, 2030F, $ Billion

Table 3: Global Drugs for Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

Table 4: Global Drugs for Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

Table 5: Global Drugs for Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

Table 6: Global Drugs for Immunotherapy Market, Split By Region, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

Table 7: Global Drugs for Immunotherapy Market, Split By Country, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

Table 8: Asia-Pacific, Drugs for Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

Table 9: Asia-Pacific, Drugs for Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

Table 10: Asia-Pacific, Drugs for Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

View More Press Releases:

https://www.thebusinessresearchcompany.com/press-release.aspx

About The Business Research Company:

The Business Research Company is a Business Intelligence Company which excels in company, market and consumer research. The company has specialist consultants in different industries including manufacturing, healthcare, financial services and technology. It has offices in the UK, the US and India and a network of trained researchers in 15 countries globally.

Contact Information

The Business Research Company

https://www.thebusinessresearchcompany.com

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Email: [email protected]

#drugs for immunotherapy market #drugs for immunotherapy market size

0 notes

coolluminaryland-blog1 · 5 years ago

Text

Orphan Drugs Market Valuation will Reach US$318.5bn by the End of 2025

The global orphan drug market is eminently competitive and fragmented in nature. There are several players in the market and a pool of new players is expected to enter the competitive global orphan drug market, states an upcoming Transparency Market Research (TMR) report. The prominent players in the global orphan drug market include GlaxoSmithKline plc, Johnson & Johnson. Pfizer Inc., Novartis AG, and Celgene Corporation. These leading players are focusing on gaining a stronger foothold by investing in research and development in the drug development area. The small and medium sized players depend on support and funding extended by governments. The new entrants would have to start from scratch that is from development of basic drugs to more complex drugs like orphan drugs.

Increasing importance being given to research and development activities is projected to swell up the global orphan drug market over the forecast period. The global orphan drug market is projected to increase at a CAGR of 12.10% during the forecast period 2017 to 2025. The global orphan drug market is expected to achieve a net valuation of US$318.5bn by the end of 2025.

Ask for Discount on Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=1254

Region wise, the global orphan drug market is foretold to be predominantly held by North due to the presence of well-established medical infrastructure. Moreover, facilities like support by government in the drug development for rare diseases and rising awareness initiatives being taken by non-profit organization are expected to propel the growth in the global orphan drug market.

Rising Prevalence of Cancer to Strengthen Market

The oncology department of medicines comes across rising number of cancer patients with various types of cancer, each year. The number seems to be only increasing statistically, in order to combat the situation, there is growing need and demand for the effective drugs in the drug development area. Hence, the global orphan drug market is projected to see growth opportunities in the forthcoming years.

Buy Now : https://www.transparencymarketresearch.com/checkout.php?rep_id=1254&ltype=S

Moreover, rising awareness initiatives are projected to propel the demand for orphan drugs. Furthermore, increasing cases of metabolic disorder and cardiovascular diseases to boost the global orphan drug market towards a staggering expansion in the upcoming years.

Government Assistance to Underpin Growth

Due to unmet medical needs of chronic and rare diseases the governments across the globe are extending its support by funding the research and development activities in the drug development and discovery sector of medicines. This, in turn is predicted to bolster the growth in the global orphan drug market.

Additionally, the rising geriatric population with chronic conditions calls for effective drugs to treat the condition or keep them in control. Thus, the demand for orphan drug increases, owing to substantial growth in the global orphan drug market during the forecast period.

High cost associated with developing orphan drugs is projected to hinder the global orphan drugs market in the upcoming years. Also, lack of awareness may stagnate the market.

Nonetheless, regardless of the constraints the rising investments in research and developments by the leading players and governments initiatives to support the development of drugs is projected to expand the global orphan drugs market in the upcoming years. Further, non-profit organizations initiatives to increase the global awareness are also expected to surge the global orphan drugs market during the forecast period.

This review is based on the findings of a TMR report titled, “Orphan Drugs Market (Disease Type – Oncology, Gastrointestinal, Pulmonary, Neurology, Hematology, Cardiovascular, Metabolic disorders, Endocrinology, and Infectious diseases; Product Type – Biologic and Non-biologic; Distribution Channel – Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, and others)) – Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2017 – 2025.”

0 notes